|
Senior Member
|
|
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
|
|
|
Senior Member
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
|
One consequence of this work is that it allows clinical trials to be more effective. By taking the PD subtype into account you reduce one level of uncertainty.
The next step is to find out whether the subtypes have different causation and require different treatment. As they say in the paper, we need to understand, and this must be the PD word of the day, "clinicopathophysiologic" clustering of PD!
John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
|